OMEROS CORP 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical crossroads, balancing the excitement of its first commercial product against the lingering weight of legacy financial obligations. The transition to a revenue-generating entity is evident in the $9.9 million in initial sales and the strategic divestiture of zaltenibart, which provided a necessary capital cushion. However, the quality of the current earnings is skewed by non-cash derivative gains and the unique cost structure of early-launch inventory. Investors must now weigh the potential for YARTEMLEA to penetrate the remaining 83% of U.S. transplant centers against the risk of margin compression and debt servicing costs. While the $135.3 million cash position provides a temporary safety net, the long-term viability of Omeros depends on its ability to convert early product interest into a sustainable, high-margin cash flow that can support its broader R&D ambitions and retire its remaining convertible notes.